Our mission is to identify, develop, and commercialise medical products sourced entirely from the by-products of sustainably certified marine fisheries.

We believe our orthopaedic products will be invaluable to the health and well-being of ageing populations worldwide while establishing the Kimberley region as a vibrant new hub of biomedical research. Our long-term goal is to develop a suite of products spanning the orthopaedic, pharmaceutical, and cosmetics sectors, each derived from Australia's unique marine environment.

With planning underway to construct a state-of-the-art processing laboratory in Broome, Marine Biomedical is ideally poised to become a Western Australian biotech company of global renown. You can keep up to date with our progress here, or contact us for more information.

Derived from the nacre of Broome's silver-lipped pearl oyster (Pinctada maxima), PearlBone™ harnesses the natural process of mollusc biomineralization, unchanged for millions of years, to encourage bone formation in incidences of trauma medicine and has proven so effective in pre-clinical trials that we believe it could transform the estimated USD3 billion international bone substitute market.

Marine Biomedical intends to demonstrate its ability to manufacture PearlBone™ to the highest standard of quality to meet the strict requirements of the U.S Food and Drug Administration (FDA) and further with the Australian Therapeutic Goods Administration (TGA). To help us secure regulatory approval, we intend to establish an ISO 7 GMP (Good Manufacturing Practice) Cleanroom Facility in Broome and develop a thoroughly documented Quality Management System and operational implementation program.